menu
    • menu
    [{"orgOrder":0,"company":"ERS Genomics","sponsor":"IRBM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ERS Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ERS Genomics \/ IRBM","highestDevelopmentStatusID":"4","companyTruncated":"ERS Genomics \/ IRBM"},{"orgOrder":0,"company":"ERS Genomics","sponsor":"Lepton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ERS Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ERS Genomics \/ Lepton Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ERS Genomics \/ Lepton Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by ERS Genomics

    Menu

    ERS Genomics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ERS Genomics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            ERS Genomics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : IRBM

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement

                            Details : The license agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering for cancer, infectious diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : IRBM

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ERS Genomics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed

                            ERS Genomics

                            Ireland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Lepton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

                            Details : miRNAs are noncoding RNAs that each affects the expression of hundreds of coding genes. The Castling technology utilizes miRNA pairs that impact immune-cells activity when in the microenvironment of cancer cells.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 26, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Lepton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth